Report contents
At a glance
- Business model: Insmed sells ARIKAYCE for MAC lung disease and, after the 2025 FDA approval, Brinsupri for non-cystic fibrosis bronchiectasis. The strength is an 85.1% gross margin in Q3 2026 and a much larger oral bronchiectasis market; the obstacle is that payer coverage and step therapy decide how quickly prescriptions become net revenue.
- Financial quality: Revenue reached $0.52 billion in Q3 2026 and gross margin 85.1%, but the quarter still produced a $0.09 billion operating loss and $0.04 billion of free cash outflow. Cash of $0.40 billion against $0.57 billion of debt leaves thin capacity for a launch whose spending runs ahead of paid fills.
Business model
Business model: one rare-disease drug funds a much larger bet
Insmed sells ARIKAYCE, an inhaled liposomal form of amikacin, to adults with Mycobacterium avium complex (MAC) lung disease who have limited or no alternative treatment options. The customer is a small, aging pool of patients with underlying bronchiectasis or COPD; pulmonologists and infectious-disease specialists write the prescription, specialty pharmacies dispense it, and Medicare Part D, Japanese national insurance and European national payers cover it. ARIKAYCE generated about $360 million of net sales in 2024, essentially all of the company's revenue. Insmed is a specialty biopharmaceutical company in an expansion stage, building commercial infrastructure in the US, Japan and Europe for a second product rather than harvesting the first.
The revenue mix is simple and correspondingly exposed. Insmed discloses ARIKAYCE sales by region, with the US roughly three-quarters of the total and Japan plus a handful of European markets supplying the rest, but it does not publish patient counts, persistency or gross-to-net by country. That gap matters: reported growth can come from new patients, longer duration, price or channel mix, and only management commentary separates them in public. Unit economics resemble orphan-drug economics, with a high price for a chronic daily therapy spread over few patients and a commercial cost base built for more of them than exist. Insmed has not reported an annual operating profit since launch; gross profit funds R&D and the geographic buildout.
Bargaining power sits with the payer, not the prescriber. Insmed owns the label, the nebulizer partnership, specialty distribution and its field force, but Medicare Part D dominates the US book, so rebates and coverage-gap mechanics decide how much of list price arrives as net revenue. The narrow label is both the moat and the ceiling: "limited or no alternative treatment options" keeps the eligible population small enough to avoid the price politics aimed at mass-market drugs, and it also means growth depends on finding undiagnosed or untreated MAC patients. Cheap off-label nebulized amikacin and chronic azithromycin remain the practical alternatives in many regimens and set what payers will tolerate.
Outside the US the model is reimbursement by reimbursement. Japan pays through national insurance and revises drug prices on a fixed schedule, so volume gains are partly offset by administered cuts; Europe is a series of country negotiations, each with its own health-technology assessment and each small enough that a delayed decision costs a year of sales. Those markets explain why ARIKAYCE sales have grown faster than the US patient pool alone would suggest, but they also carry lower realized prices, and Insmed does not break out net pricing by market.
Brensocatib, an oral DPP1 inhibitor (DPP1 is an enzyme that activates neutrophil proteases), is a different business inside the same company. Non-cystic fibrosis bronchiectasis is a far larger population than MAC lung disease, therapy is chronic and oral rather than nebulized, and prescribing extends from bronchiectasis clinics into community pulmonology. Insmed has said the FDA granted priority review to the bronchiectasis application with an action date in late 2025; the commercial question starts after that decision. An oral chronic therapy should carry a lower annual price, closer payer scrutiny, step edits through generic azithromycin and a sales force several times the size of the one ARIKAYCE needs. Insmed has built a rare-disease machine of small patient numbers, high touch and reimbursement casework, and would have to run a volume business beside it.
The recurring tradeoff is price against volume, and Insmed has chosen volume. Growth has come from patient adds and new geographies rather than list-price increases, which suits a drug whose total spend is small enough to sit outside Medicare price negotiation while its per-patient cost stays visible to payers. The fragility is concentration: one product, one dominant payer type, one regulator, and cash consumption that external financing has covered.
What would overturn the judgment that this is becoming a two-franchise company is launch behavior, not the label. If prescriptions remain concentrated in the same bronchiectasis centers that already write ARIKAYCE, and coverage arrives with step edits through generic azithromycin, then brensocatib is a niche product carrying a large-company cost base and the equity is again a single $400 million franchise.
Questions worth following
- Can Insmed get brensocatib prescribed outside bronchiectasis centers?
Brensocatib's commercial value depends on reaching the community pulmonologists who treat most bronchiectasis patients. If prescribing stays with the specialist centers that already use ARIKAYCE, the launch behaves like a rare-disease product and would not justify the added sales and marketing spending.
- Can ARIKAYCE hold net price as US payer mix shifts to Medicare?
ARIKAYCE's economics depend on realized price, not list price, in a patient population that skews to Part D. If rebates and coverage rules erode net price, incremental patients add little gross profit and the franchise cannot fund the brensocatib buildout.
- Can ARIKAYCE grow outside the US as reimbursement broadens?
Ex-US markets are the cheapest source of incremental ARIKAYCE growth because the field forces already exist. Whether reimbursement converts into durable revenue determines how much gross profit is available to fund the brensocatib launch without another financing.
Financial quality
Financial quality: revenue is scaling faster than the loss
Profitability: Very weak, improving. Insmed still loses money, but the shape of the loss has changed. Gross margin reached 85.1% in the quarter ended September 30, 2026, up from 76.4% in FY2024. The quarterly net loss narrowed from $0.33 billion in FY2025 Q4 to $0.01 billion in FY2026 Q2, then widened to $0.10 billion in Q3. Revenue over the same three quarters climbed from $0.26 billion to $0.52 billion, and Q3 2026 sales were 3.7 times the $0.14 billion reported a year earlier.
Solvency: Adequate. Two equity raises did the repair work. Financing inflows of $1.34 billion in FY2024 and $0.95 billion in FY2025 lifted total equity to $0.73 billion and cut liabilities to assets from 87.7% at the end of FY2023 to 25.5% in September 2026. A current ratio of 2.86 and quick ratio of 2.59 look comfortable, but cash of $0.40 billion sits against $0.57 billion of debt.
Cash flow: Weak. Free cash flow has been negative in every year shown, and the trailing four quarters total about -$0.66 billion. Against $0.40 billion of cash that is under a year of coverage at the trailing rate; at the most recent quarter's -$0.04 billion it is more than two years. The distance between those two numbers is the company's central financial uncertainty.
| USD bn except ratios (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 Q3 | Assessment |
|---|---|---|---|---|---|---|---|
| Revenue | 0.19 | 0.25 | 0.30 | 0.36 | 0.61 | 0.52 | Strong ramp |
| Gross margin | 76.6 | 77.5 | 78.5 | 76.4 | 79.4 | 85.1 | Strong |
| Operating income | -0.38 | -0.46 | -0.71 | -0.88 | -1.18 | -0.09 | Very weak |
| Net income | -0.43 | -0.48 | -0.75 | -0.91 | -1.28 | -0.10 | Very weak |
| Net margin | -230.6 | -196.3 | -245.6 | -251.2 | -210.5 | -19.1 | Very weak |
| Operating cash flow | -0.36 | -0.40 | -0.54 | -0.68 | -0.93 | -0.04 | Weak |
| Free cash flow | -0.37 | -0.41 | -0.55 | -0.71 | -0.97 | -0.04 | Weak |
| Total liabilities/assets | 46.4 | 68.4 | 87.7 | 55.3 | 24.7 | 25.5 | Strong, improved |
| Current ratio (x) | 6.19 | 6.69 | 4.12 | 5.45 | 3.83 | 2.86 | Strong |
| Cash | 0.72 | 1.07 | 0.48 | 0.55 | 0.51 | 0.40 | Adequate |
| Total equity | 0.41 | 0.09 | -0.33 | 0.29 | 0.74 | 0.73 | Adequate |
| ROE | -126.7 | -193.2 | 614.5 | 3,926.5 | -249.3 | -13.5 | Not meaningful |
| ROA | -42.6 | -33.2 | -50.2 | -54.5 | -59.5 | -4.6 | Very weak |
*Three months ended September 30, 2026. Flow ratios and returns cover a single quarter and are not comparable with full-year figures.
The five-year record is steady top-line growth, about 34% a year from FY2021 to FY2025, paid for by shareholders and lenders. Losses widened in dollars every year through FY2025 even though gross margin held near 77–79%, because operating expense grew faster than gross profit. Operating expense in FY2025 reached roughly $1.66 billion against $0.61 billion of sales, so the $1.28 billion net loss reflects spending levels, not a weak product margin. How much of that spending was launch build versus one-time charges is not visible in these statements, and it changes how the FY2026 cost base should be read.
| USD bn except ratios (%) | FY25 Q1 | FY25 Q2 | FY25 Q3 | FY25 Q4 | FY26 Q1 | FY26 Q2 | FY26 Q3 | Assessment | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.09 | 0.11 | 0.14 | 0.26 | 0.31 | 0.42 | 0.52 | Strong | Rising steeply |
| Gross margin | 77.1 | 73.9 | 79.4 | 83.2 | 83.8 | 84.2 | 85.1 | Strong | Rising |
| Net income | -0.26 | -0.32 | -0.37 | -0.33 | -0.16 | -0.01 | -0.10 | Very weak | Narrowing, with a Q3 reversal |
| Operating cash flow | -0.26 | -0.21 | -0.22 | -0.25 | -0.22 | -0.09 | -0.04 | Weak | Improving |
| Free cash flow | -0.27 | -0.21 | -0.22 | -0.29 | -0.23 | -0.10 | -0.04 | Weak | Improving |
| Total assets | 1.80 | 2.48 | 2.36 | 2.26 | 2.08 | 2.10 | 2.23 | Adequate | Flat |
| Total liabilities | 1.70 | 1.23 | 1.42 | 1.53 | 1.37 | 1.34 | 1.50 | Adequate | Up in Q3 |
| Cash | 0.40 | 1.28 | 0.34 | 0.51 | 0.58 | 0.55 | 0.40 | Adequate | Volatile, down in Q3 |
| Receivables | 0.05 | 0.06 | 0.07 | 0.14 | 0.18 | 0.21 | 0.26 | Adequate | Tracking sales |
| Inventory | 0.10 | 0.11 | 0.12 | 0.13 | 0.13 | 0.14 | 0.16 | Adequate | Building slowly |
| Current ratio (x) | 5.86 | 6.68 | 4.63 | 3.83 | 4.47 | 3.72 | 2.86 | Strong | Falling |
Standalone quarters; fiscal quarters ending on the dates shown. Net PP&E is not disclosed for these periods.
Operating expense, not cost of goods, decides when Insmed breaks even. Quarterly operating expense has run between roughly $0.36 billion and $0.54 billion for seven quarters while gross profit rose from $0.07 billion to $0.45 billion. The leverage is real but not yet steady: the roughly $0.18 billion sequential increase in Q3 2026 spending erased the gain that had taken Q2's operating loss to about zero. If that step-up is durable launch investment, the loss stays near $0.1 billion a quarter; if it was timing, the next quarter should show it.
Working capital is not where the cash is leaking. Receivables rose from $0.05 billion to $0.26 billion across the seven quarters, roughly in step with revenue, and receivable days have held near 45. Inventory rose from $0.10 billion to $0.16 billion while quarterly cost of sales roughly tripled, so stock now covers about 2.3 quarters of sales, down from roughly five in early 2025. For the nine months to September 2026, operating cash use of $0.35 billion modestly exceeded the $0.27 billion net loss because those balances absorbed cash, but the gap is small enough to read as timing.
Capital intensity is low, so returns hinge almost entirely on margins. Free cash flow differs from operating cash flow by $0.00–0.01 billion a quarter, making capex negligible; the larger investing outflows, including $0.76 billion in FY2025 Q3, are investments or acquisitions whose return is not visible here. ROE is unusable as a gauge: the reported 3,926% for FY2024 and -249% for FY2025 come from an equity base that was briefly near zero and then negative, not from a change in earning power. ROIC is negative because operating income is negative.
What to check
- The Q3 2026 reversal. Operating expense jumped about $0.18 billion while revenue rose $0.10 billion. Disclosure should separate launch hiring and promotion from legal, manufacturing or milestone items; one quarter of that mix determines whether the loss base is $0.1 billion or near zero.
- The FY2025 investing outflow of $0.76 billion and the $1.66 billion of operating expense. If a meaningful portion of either is an acquired asset or a one-time charge, the recurring cost base is lower than the reported loss implies, and the FY2026 improvement is less of a change than it looks.
- Runway and refinancing. With $0.40 billion of cash, $0.57 billion of debt and roughly $0.08 billion of annual interest that operating income does not cover, debt maturities and covenant terms matter as much as the burn rate itself.
Two consecutive quarters of positive operating cash flow would move the cash-flow assessment from weak to adequate. Another equity raise would confirm that the launch is still being funded by shareholders.
Questions worth following
- Can Insmed's gross profit outgrow operating expenses before cash runs thin?
Gross profit rose sixfold over seven quarters while quarterly operating expense stayed in a roughly $0.36–0.54 billion band. Whether that gap keeps closing decides when Insmed stops burning cash and whether the equity base, raised twice since 2024, is sufficient.
- Will launch spending force Insmed into another equity raise?
Insmed funded years of losses with equity and convertible notes, and launch spending now precedes Brinsupri revenue. If cash falls faster than paid fills rise, another raise becomes the path of least resistance, diluting per-share value even if the commercial franchise remains intact.
- Is Insmed's reported growth reaching patients or filling the channel?
Revenue rose from $0.14 billion to $0.52 billion in four quarters. If that reflects patient demand, receivables and inventory should track sales and the 85% gross margin should hold; if it reflects stocking, later quarters give some back and the improving cash conversion stalls.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Key risksWhat could break the investment case
- Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
- SummaryOur overall judgement and what to watch next
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Insmed Inc
Insmed Inc
Business, moat and key questions
Open company page